Literature DB >> 20889574

Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials.

Mahsa Nashid1, Puja P Khanna, Daniel E Furst, Philip J Clements, Paul Maranian, James Seibold, Arnold E Postlethwaite, James S Louie, Maureen D Mayes, Harsh Agrawal, Dinesh Khanna.   

Abstract

OBJECTIVE: Although the incidence of dcSSc is higher in African-American and Hispanic populations compared with European Caucasian patients, it is not clear whether there are differences in subsequent disease course. Also, the potential impact of gender on the disease course of dcSSc is not well defined. Our objective was to assess the course of modified Rodnan skin score (MRSS), HAQ-disability index (HAQ-DI) and forced vital capacity per cent (FVC%) predicted between men vs women and three ethnic groups with dcSSc participating in three randomized clinical trials (RCTs).
METHOD: Data from RCTs (n = 495) were pooled and analysed. Baseline characteristics were compared in men vs women and among ethnic groups. A linear mixed effects model was used to assess the predictors of MRSS, HAQ-DI and FVC%. The primary independent variables were time-in-study and its interaction with gender and ethnicity. The models were adjusted for other covariates that were significant at baseline between gender and ethnicity analyses.
RESULTS: Men had lower HAQI-DI scores compared with women (P < 0.05). Among the three ethnic groups, Caucasians were older, African-Americans had lower FVC% predicted and Hispanics had greater tender joint counts (P < 0.05). The course of MRSS, HAQ-DI and FVC% predicted during the study period was not significantly different between gender and three ethnicities. Time-in-study was an independent predictor of improvement in MRSS and HAQ-DI.
CONCLUSION: Our analysis explores the influence of gender and ethnicity on disease course in RCTs. These findings are relevant to issues of future trial design.

Entities:  

Mesh:

Year:  2010        PMID: 20889574      PMCID: PMC3107588          DOI: 10.1093/rheumatology/keq294

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  Lung function testing: selection of reference values and interpretative strategies.

Authors:  A Miller
Journal:  Am Rev Respir Dis       Date:  1992-11

2.  Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial.

Authors:  Puja P Khanna; Daniel E Furst; Philip J Clements; Paul Maranian; Lilavati Indulkar; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2010-02-09       Impact factor: 7.580

3.  Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody.

Authors:  M Kuwana; J Kaburaki; F C Arnett; R F Howard; T A Medsger; T M Wright
Journal:  Arthritis Rheum       Date:  1999-03

4.  Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.

Authors:  P J Clements; W K Wong; E L Hurwitz; D E Furst; M Mayes; B White; F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V Steen; R Martin; D Collier; A Weinstein; E Lally; J Varga; S Weiner; B Andrews; M Abeles; J Seibold
Journal:  Arthritis Rheum       Date:  1999-11

5.  Racial differences in scleroderma among women in Michigan.

Authors:  T J Laing; B W Gillespie; M B Toth; M D Mayes; R H Gallavan; C J Burns; J R Johanns; B C Cooper; B J Keroack; M C Wasko; J V Lacey; D Schottenfeld
Journal:  Arthritis Rheum       Date:  1997-04

Review 6.  Scleroderma epidemiology.

Authors:  Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

7.  The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years.

Authors:  Birgitta Tengstrand; Monica Ahlmén; Ingiäld Hafström
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

8.  Severe restrictive lung disease in systemic sclerosis.

Authors:  V D Steen; C Conte; G R Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1994-09

9.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

Authors:  Maureen D Mayes; James V Lacey; Jennifer Beebe-Dimmer; Brenda W Gillespie; Brenda Cooper; Timothy J Laing; David Schottenfeld
Journal:  Arthritis Rheum       Date:  2003-08

10.  Gender role expectations of pain: relationship to experimental pain perception.

Authors:  Emily A Wise; Donald D Price; Cynthia D Myers; Marc W Heft; Michael E Robinson
Journal:  Pain       Date:  2002-04       Impact factor: 7.926

View more
  10 in total

1.  Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children.

Authors:  Shinichi Takatsuki; Jennifer B Soep; Michelle Calderbank; David Dunbar Ivy
Journal:  Pediatr Cardiol       Date:  2011-03-30       Impact factor: 1.655

Review 2.  Assessment of skin involvement in systemic sclerosis.

Authors:  Gábor Kumánovics; Márta Péntek; Sangmee Bae; Daniela Opris; Dinesh Khanna; Daniel E Furst; László Czirják
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

3.  Systemic sclerosis manifestations and clinical outcomes in Hispanics/Latinos of the American Southwest.

Authors:  Sharon E Nunez; Angie Ariza-Hutchinson; Roderick A Fields; Jaime A Vondenberg; Rosemina A Patel; N Suzanne Emil; Maheswari Muruganandam; James I Gibb; Janet L Poole; Wilmer L Sibbitt
Journal:  J Scleroderma Relat Disord       Date:  2022-04-10

Review 4.  Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials.

Authors:  David Roofeh; Alain Lescoat; Dinesh Khanna
Journal:  Expert Opin Emerg Drugs       Date:  2020-10-26       Impact factor: 4.191

5.  Limited mouth opening secondary to diffuse systemic sclerosis.

Authors:  Tomoko Wada; Saravanan Ram
Journal:  Case Rep Dent       Date:  2013-12-18

6.  Comparison of clinical and serological parameters in female and male patients with systemic sclerosis.

Authors:  Ewa Wielosz; Maria Majdan; Magdalena Dryglewska; Dorota Suszek
Journal:  Reumatologia       Date:  2016-02-11

7.  Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Authors:  Nadia D Morgan; Ami A Shah; Maureen D Mayes; Robyn T Domsic; Thomas A Medsger; Virginia D Steen; John Varga; Mary Carns; Paula S Ramos; Richard M Silver; Elena Schiopu; Dinesh Khanna; Vivien Hsu; Jessica K Gordon; Heather Gladue; Lesley A Saketkoo; Lindsey A Criswell; Chris T Derk; Marcin A Trojanowski; Victoria K Shanmugam; Lorinda Chung; Antonia Valenzuela; Reem Jan; Avram Goldberg; Elaine F Remmers; Daniel L Kastner; Fredrick M Wigley; Pravitt Gourh; Francesco Boin
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China.

Authors:  Shasha Hu; Yong Hou; Qian Wang; Mengtao Li; Dong Xu; Xiaofeng Zeng
Journal:  Arthritis Res Ther       Date:  2018-10-22       Impact factor: 5.156

9.  Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.

Authors:  Xiao-Yu Cao; Sha-Sha Hu; Dong Xu; Meng-Tao Li; Qian Wang; Yong Hou; Xiao-Feng Zeng
Journal:  Int J Rheum Dis       Date:  2018-12-28       Impact factor: 2.454

10.  Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II.

Authors:  Elizabeth R Volkmann; Virginia Steen; Ning Li; Michael D Roth; Philip J Clements; Daniel E Furst; Shervin Assassi; Dinesh Khanna; Grace-Hyun J Kim; Jonathan Goldin; Robert M Elashoff; Donald P Tashkin
Journal:  ACR Open Rheumatol       Date:  2020-12-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.